Postdoctoral Research Scientist
Christophe Ravaud studied Genetics and Development at University Nice Cote d’Azur, in France where he completed his PhD from 2013 to 2017.
His PhD research was about the side effects of the HAART therapy on the human adipose stem cells, focusing on their self-renewal and differentiation into white and brown adipocytes. After completion of his PhD, Christophe moved to Oxford and started as a Postdoctoral Research Scientist in Prof. Paul Riley’s group at DPAG and Oxstem, an Oxford spin-out which plans to develop small molecule drugs that can activate repair mechanisms that already exist within the body.
Currently, Christophe is working on a project investigating small molecule stimulation of cardiac lymphangiogenesis, which occurs post-myocardial infarction, in order to optimise the local injury environment for tissue repair after a heart attack.